Navigation Links
NeoStem Announces Closing of Public Offering for $16,500,000 in Gross Proceeds
Date:7/22/2011

NEW YORK, July 22, 2011 /PRNewswire/ -- NeoStem, Inc. (NYSE Amex: NBS) ("NeoStem" or the "Company"), an international biopharmaceutical company, today announced the closing of an underwritten public offering of 13,750,000 units at $1.20 per unit.

Each unit consists of one share of common stock and a warrant to purchase 0.75 of a share of common stock with a per share exercise price of $1.45. Lazard Capital Markets LLC and JMP Securities LLC acted as joint bookrunners.  Morgan Joseph TriArtisan LLC, Maxim Group LLC and National Securities Corporation acted as co-managers of the offering.  

Gross proceeds were $16,500,000, prior to deducting underwriting discounts and commissions and offering expenses payable by the Company. These funds will be used for working capital purposes, including research and development of cell therapeutic product candidates, expansion of business units and other general corporate purposes.

Dr. Robin L. Smith, Chairman and CEO of NeoStem stated, "This financing and recent signing of a definitive agreement to acquire Amorcyte with a Phase II-ready asset for acute myocardial infarction mark the beginning of our transition to a developer of cell therapeutics and capitalizes on our purchase of Progenitor Cell Therapy (PCT) earlier this year."

About NeoStem, Inc.NeoStem, Inc. ("NeoStem") is engaged in the development and manufacturing of cell-based therapies. Its January, 2011 acquisition of Progenitor Cell Therapy ("PCT"), and its July 14, 2011 announcement of the signing of a merger agreement to acquire Amorcyte, Inc. ("Amorcyte"), position NeoStem to achieve its mission of capturing the paradigm shift to cell therapy.

PCT gives NeoStem not only access to a world class contract manufacturing cell therapy company but provides NeoStem a platform and expertise around the evaluation, development and regulatory requirements to develop autologous, allogeneic, immunomodulatory and vaccine-based therapeutics.

NeoStem also holds the worldwide exclusive license to VSEL™ Technology, which uses very small embryonic-like stem cells, shown to have several physical characteristics that are generally found in embryonic stem cells, and is pursuing the licensing of other technologies for therapeutic use. NeoStem owns 80% of Athelos Corporation, a company developing a T-cell therapeutic with potential in a range of auto-immune conditions such as graft versus host disease, asthma and diabetes. NeoStem's acquisition of Amorcyte, once the transaction is completed, will give the Company a Phase 2 asset for the treatment of Acute Myocardial Infarctions and a Phase 1 asset for Congestive Heart Failure. NeoStem will own 100% of the worldwide rights to the Amorcyte programs.

Furthermore, NeoStem is building its Chinese presence by establishing an operations lab for cell-based manufacturing in Beijing, as well as commercializing cellular therapies in China through the establishment of relationships with a network of hospitals.

NeoStem also owns a majority-interest in Suzhou Erye Pharmaceutical Company Limited, a world class manufacturing and distribution operation of generic antibiotics in China, with reported revenues of $69 million in 2010.

http://www.neostem.com.

Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward looking statements include statements herein with respect to successful execution of the Company's strategy, including the integration of PCT's operations, the successful closing of the Amorcyte acquisition and the successful development of any cell therapeutic product, about which no assurances can be given. The Company's actual results could differ materially from those anticipated in these forward- looking statements as a result of various factors.

Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the "Risk Factors" described in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on April 6, 2011, its Prospectus Supplement dated on July 19, 2011 as well as other periodic filings made with the Securities and Exchange Commission. The Company's further development is highly dependent on future medical and research developments and market acceptance, which is outside its control.For more information, please contact:NeoStem, Inc.Robin Smith, CEOPhone: +1-212-584-4174Email: rsmith@neostem.comWeb:   http://www.neostem.com
'/>"/>

SOURCE NeoStem, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. The Pontifical Council for Culture and NeoStem Announce Steps Forward in their Partnership to Advance Adult Stem Cell Research
2. NeoStem to Present at Two Investor Events This Month
3. NeoStem Announces the Addition of Jason Kolbert as Vice President of Strategic Business Development
4. NeoStem to Present at Cowen Group 31st Annual Health Care Conference on March 7 and 8
5. NeoStem to Present at Wall Street Forum 2011 Financial Conference on Tuesday, March 1
6. NeoStem Acquires Progenitor Cell Therapy
7. NeoStem Chairman and CEO to be Honored at the Moves 2010 Power Women Awards
8. NeoStem Presented at NASDAQ MarketSite in New York to Discuss Entry Into Merger Agreement With Progenitor Cell Therapy
9. FOX Business Network Airing In-Depth Look at NeoStem
10. NeoStem to Present at Rodman & Renshaws 12th Annual Healthcare Conference
11. NeoStem Provides Second Quarter Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... (PRWEB) , ... March 29, 2017 , ... ComplianceOnline, the ... subjects has announced its 3rd Annual Medical Device Summit 2017 venue and speaker lineup. ... Parker House Hotel, in Boston, MA. , The Omni Parker House Hotel, which is ...
(Date:3/29/2017)... DC (PRWEB) , ... March 29, 2017 , ... ... announced today that it is exhibiting in booth 513 at the Association of ... Washington, DC Downtown Hotel, March 29-31. , CANCERSCAPE unites key stakeholders from ...
(Date:3/29/2017)... 29, 2017 /PRNewswire/ -  GeneNews Limited (TSX:GEN) ("GeneNews" or ... a new risk stratification test for breast cancer, via its ... Laboratory ("IDL"). BreastSentry incorporates a blood-based biomarker test with a ... for developing breast cancer.   ... BreastSentry measures the fasting plasma levels ...
(Date:3/28/2017)... ... March 28, 2017 , ... Mass spectrometry is becoming ... of this technology is driven by its potential to perform challenging analyses in complex ... some challenges that must be addressed for it to be routinely used for medical ...
Breaking Biology Technology:
(Date:3/9/2017)... , March 9, 2017 4Dx has ... World Lung Imaging Workshop at the University of Pennsylvania. ... invited to deliver the latest data to world leaders ... event brings together leaders at the forefront of the ... lung imaging. "The quality of the ...
(Date:3/7/2017)... BRIGHTON, England , March 7, 2017 Brandwatch ... been chosen by The Prince,s Trust to uncover insights ... insights across The Trust. The UK,s leading youth charity ... track social campaign results and get a better understanding of the ... ...
(Date:3/6/2017)... Calif. , March 6, 2017 ... and sales technology, today announced Predictive Sales Coach ... for infusing actionable sales intelligence into Salesforce. This ... automatically enable their sales organizations with deep knowledge ... that allow for intelligent engagement. Predictive Sales Coach ...
Breaking Biology News(10 mins):